4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole → 2-(2-(1H-indazol-4-yl)-9-methyl-6-morpholino-9H-purin-8-yl)propan-2-ol
Reaktionsgleichung
Cl[C:2]1[N:10]=[C:9]2[C:5]([N:6]=[C:7]([C:12]([OH:15])([CH3:14])[CH3:13])[N:8]2[CH3:11])=[C:4]([N:16]2[CH2:21][CH2:20][O:19][CH2:18][CH2:17]2)[N:3]=1.CC1(C)C(C)(C)OB([C:30]2[CH:38]=[CH:37][CH:36]=[C:35]3[C:31]=2[CH:32]=[N:33][NH:34]3)O1>>[NH:34]1[C:35]2[C:31](=[C:30]([C:2]3[N:10]=[C:9]4[C:5]([N:6]=[C:7]([C:12]([OH:15])([CH3:14])[CH3:13])[N:8]4[CH3:11])=[C:4]([N:16]4[CH2:21][CH2:20][O:19][CH2:18][CH2:17]4)[N:3]=3)[CH:38]=[CH:37][CH:36]=2)[CH:32]=[N:33]1Komponenten
3
Versuchsvorschrift
Crude 2-(2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)propan-2-ol was reacted with 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole via Procedure A and purified via reverse phase HPLC to give 56.6 mg of 132 as a white solid. MS (Q1) 394.3 (M)+
Aufarbeitung
- custompurified via reverse phase HPLC